<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00899977</url>
  </required_header>
  <id_info>
    <org_study_id>TC-5214-23-CRD-002</org_study_id>
    <nct_id>NCT00899977</nct_id>
  </id_info>
  <brief_title>TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Sequential Group Pilot Study to Assess Safety, Tolerability, and Effectiveness of TC-5214 as Augmentation Therapy in Patients With Refractory Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targacept Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targacept Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot study of subjects with refractory hypertension (on 3 concomitant agents with SBP &gt;&#xD;
      140 mmHg and a DBP &gt; 90 mmHg) randomized in a double-blind fashion to receive 4 single&#xD;
      escalating doses of study medication in clinic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      12 subjects with refractory hypertension will be randomized in a double-blind fashion to&#xD;
      receive single escalating doses of study medication in-clinic: on Day 1 (1mg), Day 8 (2mg),&#xD;
      Day 15 (4mg) and Day 22 (8mg). On each of these 4 days, 10 subjects will receive TC-5214, and&#xD;
      2 subjects will receive placebo. Placebo treatments will be pooled across the 4 days of&#xD;
      single-dose to produce an equivalent reference cohort (n = 8) for each treatment dose (n=10).&#xD;
      Following the single-dose administration of 8mg in the clinic on Day 22, subjects will&#xD;
      continue with two weeks (Days 23 - 35) of outpatient self-administration of TC-5214 (4mg BID;&#xD;
      n = 6), or matching placebo (BID; n = 6). On Day 36, subjects will return for a final&#xD;
      in-clinic dose of either TC-5214 (4mg, n = 6) or placebo (n = 6). There will be a 1-week&#xD;
      follow-up period at the end of the treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business reasons&#xD;
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean difference between TC-5214 and placebo in change at 3 hours from baseline SBP</measure>
    <time_frame>Following dosing, 3 manual seated BP measurements and orthostatic BP measurements will be obtained in an identical fashion, at 30 minutes post-dose and at 1, 2, 3, 4, 5, 6, 7, and 8 hrs post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of TC-5214 in patients with refractory hypertension and obtain preliminary dose-response estimates</measure>
    <time_frame>Days 1, 8, 15, 22 and 36</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Refractory Hypertension</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects may receive a single, oral dose of placebo (capsule) in one of 4 crossover periods. Also, subjects may receive placebo orally, twice daily for 14 days in the last phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg TC-5214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects may receive a single, oral capsule of 1 mg TC-5214 in one of 4 crossover periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 mg TC-5214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects may receive a single, oral capsule of 2 mg TC-5214 in one of 4 crossover periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4 mg TC-5214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects may receive a single, oral capsule of 4 mg TC-5214 in one of 4 crossover periods. Also, subjects may receive 4 mg TC-5214 orally, twice daily for 14 days in the last phase of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8 mg TC-5214</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects may receive a single, oral capsule of 8 mg TC-5214 in one of 4 crossover periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC-5214</intervention_name>
    <arm_group_label>1 mg TC-5214</arm_group_label>
    <arm_group_label>2 mg TC-5214</arm_group_label>
    <arm_group_label>4 mg TC-5214</arm_group_label>
    <arm_group_label>8 mg TC-5214</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Refractory hypertension, defined as a SBP of &gt;140mmHg and a DBP &gt; 90mmHg, on stable&#xD;
             doses of at least 3 concomitant antihypertensive treatment (which must include a&#xD;
             diuretic and an ACEI, ARB or RA) for 8 weeks prior to Screening. All approved&#xD;
             antihypertensive treatments are allowed except for alpha-adrenergic blockers,&#xD;
             hydralazine, clonidine, guanethidine, guanadrel, and rauwolfia alkaloids.&#xD;
&#xD;
          2. Stable hypertension, as defined by: a. mean SBP on Day -7 that is within 20mmHg of the&#xD;
             mean SBP on Day 1, with both mean SBPs &gt; 140mmHg; and b. mean DBP on Day -7 that is&#xD;
             within 10mm of the mean DBP on Day 1, with both mean DBPs &gt; 90mmHg.&#xD;
&#xD;
          3. Outpatient with stable housing.&#xD;
&#xD;
          4. Subjects must be able to stay in the clinic for 8 hrs on Day 1, Day 8, Day 15, Day 22,&#xD;
             and Day 36.&#xD;
&#xD;
          5. Able to give and to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any unstable medical condition other than hypertension;&#xD;
&#xD;
          2. Stage 3 hypertension (SBP &gt; 180mmHg and/or DBP &gt; 110mmHg);&#xD;
&#xD;
          3. Heart rate &gt; 100 beats per minute;&#xD;
&#xD;
          4. WOCBP who is pregnant or who is planning to become pregnant during the study;&#xD;
&#xD;
          5. History within past year of alcohol or illicit drug abuse;&#xD;
&#xD;
          6. Unable to comply with study procedures in opinion of investigator;&#xD;
&#xD;
          7. Concomitant medications for any medical condition that is uncontrolled for more than 2&#xD;
             weeks prior to study entry;&#xD;
&#xD;
          8. Current use of alpha-adrenergic blocker, hydralazine, clonidine, guanethidine,&#xD;
             guanadrel, or rauwolfia alkaloids;&#xD;
&#xD;
          9. History of myocardial infarction or angina pectoris;&#xD;
&#xD;
         10. Current seizure disorder;&#xD;
&#xD;
         11. Renal insufficiency as defined by a serum creatinine &gt; 2.0;&#xD;
&#xD;
         12. Uncontrolled hypothyroidism, vitamin B12 or folic acid deficiency;&#xD;
&#xD;
         13. History of or concurrent ileus, glaucoma, or urinary retention;&#xD;
&#xD;
         14. Inability of subject to understand and sign the ICF;&#xD;
&#xD;
         15. Known systemic infection (HBV, HCV, HIV, TB);&#xD;
&#xD;
         16. Current use of smoking cessation therapy within 4 weeks of screening;&#xD;
&#xD;
         17. Use of herbal supplements;&#xD;
&#xD;
         18. Clinically significant finding on physical exam;&#xD;
&#xD;
         19. Clinically significant laboratory or ECG abnormality, including QTcF &gt; 460 msec;&#xD;
&#xD;
         20. Participation in another clinical trial in last month;&#xD;
&#xD;
         21. Body Mass Index (BMI) &gt; 35.&#xD;
&#xD;
         22. Body weight &lt; 100 pounds.&#xD;
&#xD;
         23. Site staff or family member of study site staff.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Piedmont Medical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <disposition_first_submitted>March 15, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 13, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 23, 2012</disposition_first_posted>
  <last_update_submitted>September 3, 2013</last_update_submitted>
  <last_update_submitted_qc>September 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory hypertension</keyword>
  <keyword>hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

